These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 32638380)

  • 1. Drugging "undruggable" genes for cancer treatment: Are we making progress?
    Duffy MJ; Crown J
    Int J Cancer; 2021 Jan; 148(1):8-17. PubMed ID: 32638380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC as a target for cancer treatment.
    Duffy MJ; O'Grady S; Tang M; Crown J
    Cancer Treat Rev; 2021 Mar; 94():102154. PubMed ID: 33524794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer.
    Grześ M; Jaiswar A; Grochowski M; Wojtyś W; Kaźmierczak W; Olesiński T; Lenarcik M; Nowak-Niezgoda M; Kołos M; Canarutto G; Piazza S; Wiśniewski JR; Walerych D
    Cell Death Dis; 2024 Aug; 15(8):638. PubMed ID: 39217152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53 as a target for cancer treatment.
    Duffy MJ; Synnott NC; Crown J
    Eur J Cancer; 2017 Sep; 83():258-265. PubMed ID: 28756138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.
    Casacuberta-Serra S; González-Larreategui Í; Capitán-Leo D; Soucek L
    Signal Transduct Target Ther; 2024 Aug; 9(1):205. PubMed ID: 39164274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer.
    Soncini D; Caffa I; Patrone F; Ballestrero A; Nencioni A
    Curr Cancer Drug Targets; 2012 May; 12(4):329-38. PubMed ID: 22385509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural And Computational Perspectives of Selectively Targeting Mutant Proteins.
    Coban MA; Fraga S; Caulfield TR
    Curr Drug Discov Technol; 2021; 18(3):365-378. PubMed ID: 32160847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
    Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
    Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
    Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting p53 for the treatment of cancer.
    Duffy MJ; Synnott NC; O'Grady S; Crown J
    Semin Cancer Biol; 2022 Feb; 79():58-67. PubMed ID: 32741700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
    Chen H; Smaill JB; Liu T; Ding K; Lu X
    J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A big step for MYC-targeted therapies.
    Atibalentja DF; Deutzmann A; Felsher DW
    Trends Cancer; 2024 May; 10(5):383-385. PubMed ID: 38580534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
    Porru M; Pompili L; Caruso C; Biroccio A; Leonetti C
    J Exp Clin Cancer Res; 2018 Mar; 37(1):57. PubMed ID: 29534749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
    Wang Q; Tan R; Zhu X; Zhang Y; Tan Z; Su B; Li Y
    Oncotarget; 2016 Mar; 7(9):10064-72. PubMed ID: 26848526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.
    Cui Y; Guo G
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early modification of c-myc, Ha-ras and p53 expressions by chemical carcinogens (DMBA, MNU).
    Budán F; Varjas T; Nowrasteh G; Prantner I; Varga Z; Ember A; Cseh J; Gombos K; Pázsit E; Gobel G; Bauer M; Gracza T; Arany I; Perjési P; Ember I; Kiss I
    In Vivo; 2009; 23(4):591-8. PubMed ID: 19567395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Research Progress of Direct KRAS G12C Mutation Inhibitors.
    Yang A; Li M; Fang M
    Pathol Oncol Res; 2021; 27():631095. PubMed ID: 34257597
    [No Abstract]   [Full Text] [Related]  

  • 20. Taking on challenging targets: making MYC druggable.
    Horiuchi D; Anderton B; Goga A
    Am Soc Clin Oncol Educ Book; 2014; ():e497-502. PubMed ID: 24857145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.